Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia
Dan F. Spandau, … , Robert Hoopes, Jeffrey B. Travers
Dan F. Spandau, … , Robert Hoopes, Jeffrey B. Travers
Published August 24, 2021
Citation Information: J Clin Invest. 2021;131(19):e150972. https://doi.org/10.1172/JCI150972.
View: Text | PDF
Clinical Research and Public Health Dermatology

Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia

  • Text
  • PDF
Abstract

BACKGROUND The loss of insulin-like growth factor 1 (IGF-1) expression in senescent dermal fibroblasts during aging is associated with an increased risk of nonmelanoma skin cancer (NMSC). We tested how IGF-1 signaling can influence photocarcinogenesis during chronic UVB exposure to determine if fractionated laser resurfacing (FLR) of aged skin, which upregulates dermal IGF-1 levels, can prevent the occurrence of actinic keratosis (AK) and NMSC.METHODS A human skin/immunodeficient mouse xenografting model was used to test the effects of a small molecule inhibitor of the IGF-1 receptor on chronic UVB radiation. Subsequently, the durability of FLR treatment was tested on a cohort of human participants aged 65 years and older. Finally, 48 individuals aged 60 years and older with considerable actinic damage were enrolled in a prospective randomized clinical trial in which they underwent a single unilateral FLR treatment of one lower arm. Numbers of AKs/NMSCs were recorded on both extremities for up to 36 months in blinded fashion.RESULTS Xenografting studies revealed that chronic UVB treatment with a topical IGF-1R inhibitor resulted in a procarcinogenic response. A single FLR treatment was durable in restoring appropriate UVB response in geriatric skin for at least 2 years. FLR resulted in sustained reduction in numbers of AKs and decreased numbers of NMSCs in the treated arm (2 NMSCs) versus the untreated arm (24 NMSCs).CONCLUSION The elimination of senescent fibroblasts via FLR reduced the procarcinogenic UVB response of aged skin. Thus, wounding therapies are a potentially effective prophylaxis for managing high-risk populations.TRIAL REGISTRATION ClinicalTrials.gov (NCT03906253).FUNDING National Institutes of Health, Veterans Administration.

Authors

Dan F. Spandau, Roy Chen, Jeffrey J. Wargo, Craig A. Rohan, David Southern, Angela Zhang, Mathew Loesch, Jonathan Weyerbacher, Sunil S. Tholpady, Davina A. Lewis, Matthew Kuhar, Kenneth Y. Tsai, Amber J. Castellanos, Michael G. Kemp, Michael Markey, Elizabeth Cates, Amy R. Williams, Christina Knisely, Sabina Bashir, Ryan Gabbard, Robert Hoopes, Jeffrey B. Travers

×

Figure 4

FLR leads to lasting protection from inappropriate UVB responses in geriatric skin.

Options: View larger image (or click on image) Download as PowerPoint
FLR leads to lasting protection from inappropriate UVB responses in geri...
At 1 (A) or 2 (B) years following treatment with FLR to localized areas of skin, geriatric volunteers were UVB irradiated at the site treated with FLR and at an untreated control site. Biopsies were removed 24 hours after UVB exposure and assayed for the presence of basal layer cells that expressed both the proliferative marker Ki67 and markers of UVB-induced DNA damage (thymine dimers [TDs]; clone KTM53). In A and B, each dot represents a participant and lines between the No Txt and FLR columns indicate results from the same volunteer. Solid dark lines indicate the mean. Ten participants were analyzed for either 1 year or 2 years after FLR. FLR-treated sites demonstrated a significant reduction in double-labeled cells compared with untreated sites (P < 0.007, Student t test) at both 1 and 2 years after FLR. (C) The relative level of IGF-1 mRNA in each biopsy was determined by QPCR, standardized using the expression of the housekeeping gene β2-microglobulin. The black bar indicates the average and gray boxes represent the standard deviation of assays from 11 individuals (1 year after FLR) or 9 individuals (2 years after FLR). P values shown are derived from 2-tailed Student t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts